Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of JW0104+C2402 in Hypertension and Dyslipidemia
NCT06643130Phase 3Recruiting
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Dec 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of JW0104, C2402 in hypertension (HTN), dyslipidemia, sponsored by JW Pharmaceutical Corporation. Started Dec 2024; status: recruiting.
02
Drugs
JW0104C2402
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT06643130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06643130.